Education
About Us
Working with TipRanks
Follow Us
10X Genomics (TXG)
NASDAQ:TXG
Total Valuation
10x Genomics has a market cap or net worth of $2.66B. The enterprise value is $2.34B.
Market Cap$2.66B
Enterprise Value$2.34B
Share Statistics
10x Genomics has 117,673,386 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding117,673,386
Owned by Insiders2.28%
Owned by Institutions27.96%
Financial Efficiency
10x Genomics’s return on equity (ROE) is -0.05 and return on invested capital (ROIC) is -12.34%.
Return on Equity (ROE)-0.05
Return on Assets (ROA)-0.04
Return on Invested Capital (ROIC)-12.34%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee492.21K
Profits Per Employee-33.34K
Employee Count1,306
Asset Turnover0.62
Inventory Turnover3.53
Valuation Ratios
The current PE Ratio of 10x Genomics is ―. 10x Genomics’s PEG ratio is 0.61.
PE Ratio―
PS Ratio3.17
PB Ratio2.56
Price to Fair Value2.56
Price to FCF15.64
Price to Operating Cash Flow19.44
PEG Ratio0.61
Income Statement
In the last 12 months, 10x Genomics had revenue of 642.82M and earned -43.54M in profits. Earnings per share was -0.35.
Revenue642.82M
Gross Profit443.88M
Operating Income-110.89M
Pretax Income-39.91M
Net Income-43.54M
EBITDA-110.89M
Earnings Per Share (EPS)-0.35
Cash Flow
In the last 12 months, operating cash flow was 136.05M and capital expenditures -5.93M, giving a free cash flow of 130.12M billion.
Operating Cash Flow136.05M
Free Cash Flow130.12M
Free Cash Flow per Share1.11
Dividends & Yields
10x Genomics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.49
52-Week Price Change96.51%
50-Day Moving Average19.77
200-Day Moving Average14.86
Relative Strength Index (RSI)52.39
Average Volume (3m)2.60M
Important Dates
10x Genomics upcoming earnings date is May 6, 2026, After Close (Confirmed).
Last Earnings DateFeb 12, 2026
Next Earnings DateMay 6, 2026
Ex-Dividend Date―
Financial Position
10x Genomics as a current ratio of 4.46, with Debt / Equity ratio of 19.81%
Current Ratio4.46
Quick Ratio4.09
Debt to Market Cap0.04
Net Debt to EBITDA2.85
Interest Coverage Ratio0.00
Taxes
In the past 12 months, 10x Genomics has paid 3.64M in taxes.
Income Tax3.64M
Effective Tax Rate-0.09
Enterprise Valuation
10x Genomics EV to EBITDA ratio is -15.50, with an EV/FCF ratio of 13.21.
EV to Sales2.67
EV to EBITDA-15.50
EV to Free Cash Flow13.21
EV to Operating Cash Flow12.63
Balance Sheet
10x Genomics has $523.41M in cash and marketable securities with $157.74M in debt, giving a net cash position of $365.67M billion.
Cash & Marketable Securities$523.41M
Total Debt$157.74M
Net Cash$365.67M
Net Cash Per Share$3.11
Tangible Book Value Per Share$5.85
Margins
Gross margin is 69.05%, with operating margin of -17.25%, and net profit margin of -6.77%.
Gross Margin69.05%
Operating Margin-17.25%
Pretax Margin-6.21%
Net Profit Margin-6.77%
EBITDA Margin-17.25%
EBIT Margin-17.25%
Analyst Forecast
The average price target for 10x Genomics is $20.08, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$20.08
Price Target Upside-3.51% Downside
Analyst ConsensusModerate Buy
Analyst Count13
Revenue Growth Forecast1.92%
EPS Growth Forecast59.18%